Loading…
Regentis Biomaterials Ltd
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| INTSIntensity Therapeutics Inc | $4.25 | — | 1.4x | — | -195.88% | $13.88M |
| DAREDare Bioscience, Inc. | $0.74 | — | — | — | — | $14.24M |
| CABRCaring Brands, Inc. | $1.39 | — | — | — | -333.74% | $14.41M |
| HSCSHeartSciences Inc. | $3.03 |
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.
Company description provided by Yahoo Finance.
| — |
| 42.7x |
| — |
| -4239.91% |
| $13.65M |
| ICUSeaStar Medical Holding Corp | $3.09 | — | 3.1x | — | -356.87% | $13.62M |
| PASGPassage BIO, Inc. | $4.52 | — | 3.3x | — | -169.09% | $14.54M |